Louise Chen
Stock Analyst at Scotiabank
(3.39)
# 995
Out of 5,090 analysts
300
Total ratings
46.48%
Success rate
3.9%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Initiates: Sector Outperform | $35 | $28.46 | +22.98% | 4 | Dec 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $45 → $53 | $52.15 | +1.63% | 1 | Dec 4, 2025 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $99.72 | +20.34% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $718.36 | +7.19% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $22.26 | +259.39% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $2.92 | +208.22% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $23.59 | -40.65% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $3.85 | +211.69% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $20.74 | +165.19% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $77.26 | -28.81% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $2.40 | +525.00% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $100.49 | -50.24% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.98 | +150.84% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $38.77 | -56.15% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $71.63 | -2.28% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $20.28 | +146.55% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $9.93 | +202.11% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $19.50 | +182.05% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.26 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $47.86 | +234.31% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $46.48 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $226.08 | +6.16% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $26.03 | +72.88% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $201.93 | +6.47% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.71 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.97 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,010.31 | -12.40% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.85 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $22.84 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.87 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.27 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $220.36 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.80 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.01 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.54 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.87 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.66 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.32 | +1,857.83% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.40 | +108.33% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.22 | +251.62% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $31.20 | +60.26% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.74 | +187.36% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.37 | +2,332.43% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $1.08 | +156,249,900.00% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $290.63 | -11.23% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.31 | +3,716.79% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.34 | +1,392.54% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.93 | +467.47% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Dec 5, 2025
Initiates: Sector Outperform
Price Target: $35
Current: $28.46
Upside: +22.98%
Bristol-Myers Squibb Company
Dec 4, 2025
Maintains: Sector Perform
Price Target: $45 → $53
Current: $52.15
Upside: +1.63%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $99.72
Upside: +20.34%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $718.36
Upside: +7.19%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $22.26
Upside: +259.39%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $2.92
Upside: +208.22%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $23.59
Upside: -40.65%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $3.85
Upside: +211.69%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $20.74
Upside: +165.19%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $77.26
Upside: -28.81%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.40
Upside: +525.00%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $100.49
Upside: -50.24%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.98
Upside: +150.84%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $38.77
Upside: -56.15%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $71.63
Upside: -2.28%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $20.28
Upside: +146.55%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $9.93
Upside: +202.11%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $19.50
Upside: +182.05%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.26
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $47.86
Upside: +234.31%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $46.48
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $226.08
Upside: +6.16%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.03
Upside: +72.88%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $201.93
Upside: +6.47%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.71
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.97
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,010.31
Upside: -12.40%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.85
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.84
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.87
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.27
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $220.36
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.80
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.01
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.54
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.87
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.66
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.32
Upside: +1,857.83%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.40
Upside: +108.33%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.22
Upside: +251.62%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $31.20
Upside: +60.26%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.74
Upside: +187.36%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.37
Upside: +2,332.43%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $1.08
Upside: +156,249,900.00%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $290.63
Upside: -11.23%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.31
Upside: +3,716.79%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.34
Upside: +1,392.54%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.93
Upside: +467.47%